TANGO THERAPEUTICS INC (TNGX)

US87583X1090 - Common Stock

3.24  -1.94 (-37.45%)

Premarket: 3.26 +0.02 (+0.62%)

News Image
14 hours ago - Chartmill

What's going on in today's session

Top movers analysis one hour before the close of the markets on 2024-11-06: top gainers and losers in today's session.

News Image
17 hours ago - Chartmill

Here are the top movers in Wednesday's session, showcasing the stocks with significant price changes.

Keep an eye on the top gainers and losers in Wednesday's session, as they reflect the most notable price movements.

News Image
19 hours ago - Chartmill

The market is buzzing with gapping stocks on Wednesday. Let's uncover which stocks are experiencing notable gaps during today's session.

Let's have a look at the gap up and gap down stocks in today's session.

News Image
21 hours ago - Chartmill

Curious about the stocks that are showing activity before the opening bell on Wednesday?

As we await the opening of the US market on Wednesday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.

News Image
4 months ago - Market News Video

TNGX Crosses Above Key Moving Average Level

News Image
6 months ago - Medivir

MedivirĀ“s licensee, Tango Therapeutics, has discontinued development of its TNG348 clinical program

/PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet...

News Image
6 months ago - InvestorPlace

TNGX Stock Earnings: Tango Therapeutics Misses EPS, Misses Revenue for Q1 2024

TNGX stock results show that Tango Therapeutics missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.

News Image
6 months ago - BusinessInsider

TNGX Stock Earnings: Tango Therapeutics Misses EPS, Misses Revenue for Q1 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Tango Therapeutics (NASDAQ:TNGX) just reported results for the first quarter of...

News Image
8 months ago - InvestorPlace

TNGX Stock Earnings: Tango Therapeutics Misses EPS, Misses Revenue for Q4 2023

TNGX stock results show that Tango Therapeutics missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of 2023.

News Image
8 months ago - BusinessInsider

TNGX Stock Earnings: Tango Therapeutics Misses EPS, Misses Revenue for Q4 2023

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Tango Therapeutics (NASDAQ:TNGX) just reported results for the fourth quarter o...

News Image
8 months ago - Tango Therapeutics, Inc.

Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline at the American Association for Cancer Research (AACR) Annual Meeting 2024

BOSTON, March 05, 2024 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and...

News Image
9 months ago - FinancialNewsMedia

Pancreatic Cancer Treatments Poised for Major Advances in 2024

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:INCY),(NASDAQ:TNGX),(NASDAQ:RYZB),(NYSE:BMY) EQNX::TICKER_END

News Image
9 months ago - USA News Group

Pancreatic Cancer Treatments Poised for Major Advances in 2024

/PRNewswire/ -- USA News Group - One of the more worrying storylines of 2023 was the rising incidence of early-onset pancreatic cancer. As well, the deadly...

News Image
9 months ago - Tango Therapeutics, Inc.

Tango Therapeutics to Present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference

BOSTON, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and...

News Image
10 months ago - Tango Therapeutics, Inc.

Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, Mass., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering...

News Image
10 months ago - Medivir

MedivirĀ“s licensee, Tango Therapeutics, has dosed the first patient with TNG348, a novel USP1 inhibitor, in a phase 1/2 clinical study

/PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet...